Larry Ereshefsky, PharmD, provided Phase 3 data on brilaroxazine for schizophrenia.

Published Date: 09 May 2024

Phase 3 RECOVER trial evaluating brilaroxazine at 50 mg and 15 mg for acute schizophrenia was reviewed by Larry Ereshefsky, PharmD, in an interview with HCPLive.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belgian Algorithm Reshapes Endometrial Cancer Care

2.

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

3.

Nuclear missile workers are contracting cancer: They blame the bases

4.

On all CAR-T products, the FDA is calling for a new boxed warning.

5.

ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot